Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Sebastiano Buti; Maddalena Donini; Melissa Bersanelli; Alessia Gattara; Francesco Leonardi; Rodolfo Passalacqua

doi:10.1007/s40268-018-0234-z

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Drugs R D. 2018 Jun;18(2):163. doi: 10.1007/s40268-018-0234-z.

Authors

Sebastiano Buti¹, Maddalena Donini², Melissa Bersanelli³, Alessia Gattara¹, Francesco Leonardi¹, Rodolfo Passalacqua²

Affiliations

¹ Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy.
² Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.
³ Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy. bersamel@libero.it.

Abstract

In the Original Publication of the article, In Introduction part, 7th line, the value "5-100nM" has been published incorrectly. The correct value should read as "Plasma concentration of 50-100ng/ml". In the Original Publication of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown in the following page.

Publication types

Published Erratum